Investors
MED-EL Medical Electronics
MED-EL Medical Electronics, a leader in implantable hearing solutions, is driven by a mission to overcome hearing loss as a barrier to communication and quality of life. The Austrian-based, privately owned business was co-founded by industry pioneers Ingeborg and Erwin Hochmair, whose ground-breaking research led to the development of the world’s first micro-electronic multi-channel cochlear implant (CI), which was successfully implanted in 1977 and was the basis for what is known as the modern CI today. This laid the foundation for the successful growth of the company in 1990, when they hired their first employees. To date, MED-EL has more than 2,900 employees from around 90 nations and 30 locations worldwide.
InfectoPharm Arzneimittel und Consilium GmbH
InfectoPharm Arzneimittel und Consilium GmbH specializes in the development of new and existing medications and medical products. Since 1988, the family-run German company has distinguished itself as a courageous pioneer in the industry. The portfolio currently includes around 140 preparations with numerous innovations in the fields of paediatrics, infectious diseases, dermatology and ENT medicine. The consiliumservice is available to healthcare professionals free of charge as a product-neutral consulting and knowledge transfer service.
The InfectoPharm group includes subsidiaries in Austria, Italy, France and the United Kingdom, as well as the German subsidiaries Pädia GmbH, Sonormed GmbH and Beyvers GmbH. With more than 450 employees, the group generates annual sales of around €300 million, with an average growth rate of over 10 percent. InfectoPharm regularly receives awards from the medical community – such as the “Golden Tablet” – or as “Most Crisis-Proof Employer”, “Most Crisis-Proof Company”, “Most Innovative Company” from the business sector.
Since the beginning of 2025, InfectoPharm has not only provided AudioCure with financial support for the development of new active substances, but has also expanded their knowledge base through its scientific and commercial expertise.
HTGF – High-Tech Gründerfonds
HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more than 770 start-ups and achieved over 190 successful exits.
Fund investors in the public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital as well as 45 companies and family offices.
Dr. Jürgen Schumacher
As business angel, shareholder and board member, Dr. Schumacher has been involved with AudioCure since its foundation. As a serial entrepreneur, Dr. Schumacher has co-founded a number of highly successful biotech companies. These include QIAGEN, NewLab, BioQuality AG, Evotec Biosystems and BiBiTec. He currently serves as the CEO of Algiax Pharmaceuticals GmbH. He is also shareholder and a member of the advisory board of a number of biotech companies as well as a member of academic societies. With over 30 years experience in the biotech industry, Dr. Schumacher continues to be instrumental to AudioCure´s success.